Heron Therapeutics Inc (NASDAQ:HRTX) VP Kimberly Manhard sold 7,584 shares of the business’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total transaction of $151,680.00. Following the completion of the sale, the vice president now directly owns 7,584 shares of the company’s stock, valued at $151,680. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of Heron Therapeutics Inc (HRTX) opened at $21.40 on Friday. Heron Therapeutics Inc has a twelve month low of $12.25 and a twelve month high of $22.00. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02. The company has a market cap of $1,382.44, a PE ratio of -5.65 and a beta of 2.13.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The business had revenue of $8.57 million during the quarter, compared to analyst estimates of $8.12 million. sell-side analysts expect that Heron Therapeutics Inc will post -3.38 earnings per share for the current year.
Large investors have recently bought and sold shares of the company. Legal & General Group Plc raised its holdings in shares of Heron Therapeutics by 26.6% in the 2nd quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 2,383 shares in the last quarter. Quantbot Technologies LP raised its holdings in shares of Heron Therapeutics by 2,619.6% in the 2nd quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after purchasing an additional 12,024 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of Heron Therapeutics in the 3rd quarter valued at about $206,000. Jane Street Group LLC bought a new stake in shares of Heron Therapeutics in the 3rd quarter valued at about $223,000. Finally, HighTower Advisors LLC raised its holdings in shares of Heron Therapeutics by 11.4% in the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 1,700 shares in the last quarter. Institutional investors and hedge funds own 98.78% of the company’s stock.
Several equities research analysts have issued reports on the stock. Cantor Fitzgerald set a $31.00 price objective on shares of Heron Therapeutics and gave the company a “buy” rating in a research report on Friday, January 5th. Zacks Investment Research cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. ValuEngine raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Mizuho assumed coverage on shares of Heron Therapeutics in a research report on Tuesday, September 26th. They issued a “buy” rating and a $28.00 price objective for the company. Finally, BidaskClub raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Heron Therapeutics currently has a consensus rating of “Buy” and an average price target of $28.82.
COPYRIGHT VIOLATION WARNING: “Kimberly Manhard Sells 7,584 Shares of Heron Therapeutics Inc (HRTX) Stock” was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.thelincolnianonline.com/2018/01/14/kimberly-manhard-sells-7584-shares-of-heron-therapeutics-inc-hrtx-stock.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.